4591.T
RIBOMIC Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 83.00
−5.68%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 3.0M | 2.0M | 351.9M | 65.0M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 399.0M | 406.1M | 385.0M | 351.9M | 360.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 399.0M | 406.1M | 385.0M | 351.9M | 360.8M |
| Cost and Expenses | 275.0M | 1.2B | 1.1B | 1.5B | 1.9B |
| Operating Income (EBIT) | (1.1B) | (1.2B) | (1.1B) | (1.1B) | (1.8B) |
| Non-Operating | |||||
| Interest Income | — | 5.5M | 1.7M | 361.0K | 1.4M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 25.0M | 68.6M | 35.7M | 133.4M | 136.7M |
| Non-Operating Income (excl Interest) | 2.6M | 76.6M | 38.5M | 136.7M | 145.7M |
| EBT (Pre-Tax Income) | (1.0B) | (1.1B) | (1.0B) | (1.0B) | (1.7B) |
| Income Tax Expense | 1.4M | 1.2M | 1.2M | 1.2M | 1.2M |
| Bottom Line | |||||
| Net Income | (1.0B) | (1.1B) | (1.0B) | (1.0B) | (1.7B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.0B) | (1.1B) | (1.0B) | (1.0B) | (1.7B) |
| Per Share | |||||
| Basic EPS | (¥23) | (¥23) | (¥25) | (¥29) | (¥53) |
| Diluted EPS | (¥23) | (¥23) | — | — | — |
| Revenue Per Share | ¥0 | ¥0 | ¥0 | ¥10 | ¥2 |
| Shares | |||||
| Basic Shares Outstanding | 48.1M | 49.6M | 40.4M | 35.7M | 31.1M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | (571.4M) | (1.2B) | (1.0B) | (1.1B) | (1.8B) |
| D&A | 2.6M | 4.0M | 918.0K | 10.5M | 480.0K |
| EBIT | (1.1B) | (1.2B) | (1.1B) | (1.1B) | (1.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026